The Use of Ketamine as an Anaesthetic During Electroconvulsive Therapy (KANECT)

• ClinicalTrials.gov Identifier: NCT01306760
• Recruitment Status: Completed
• First Posted: March 2, 2011
• Last Update Posted: September 8, 2016
• Sponsor: University of Aberdeen
• Collaborators: NHS Grampian; Chief Scientist Office of the Scottish Government
• Information provided by (Responsible Party): University of Aberdeen

Tracking Information

• First Submitted Date: March 1, 2011
• First Posted Date: March 2, 2011
• Last Update Posted Date: September 8, 2016
• Study Start Date: March 2011
• Actual Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: March 1, 2011)

Change in depressive symptoms [ Time Frame: After 4th treatment ]

The primary outcome measure will be change in depressive symptoms after the fourth ECT treatment. This will be assessed by the change in MADRS and 17-item HDRS scores between start of treatment and this timepoint.

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: March 1, 2011)

• Cognitive side-effects [ Time Frame: 2 months ]
  This will be assessed using the spatial recognition test from the CANTAB battery. This test was chosen as previous research has shown that this test is most sensitive to anterograde memory impairments associated with ECT. By administering this test before, during (after 4th treatment) and after treatment (immediately following and at 1 month follow-up) we will be able to determine whether ketamine can reduce the anterograde memory dysfunction as compared to propofol.
• Change in depressive symptoms after treatment [ Time Frame: 2 months ]
  The secondary measure of treatment efficacy will be assessed by the change in MADRS and 17-item HADRS scores immediately after treatment and at 1 month follow-up. Secondly, this will be assessed by the number of treatments required to achieve remission of symptoms, as judged by treating clinicians. By monitoring the number of treatments required we will be able to assess whether ketamine can reduce the number of ECT treatments required.

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: The Use of Ketamine as an Anaesthetic During Electroconvulsive Therapy
• Official Title: The Use of Ketamine as an Anaesthetic During Electroconvulsive Therapy (ECT) for Depression: Does it Improve Treatment Outcome?
• Brief Summary: The main aim of this research is to ascertain whether Ketamine would be a more effective anaesthetic for Electroconvulsive Therapy (ECT) than the standard anaesthetic. In doing so the investigators aim to examine the effect of ketamine on ratings of depressive symptoms, the number of required ECT treatments, and the effect of this anaesthetic on memory.

Detailed Description

According to WHO statistics, depression is amongst the leading causes of disability worldwide. In its more severe forms, it can be life threatening. The most severe forms of depression, or those that fail to respond to chemical treatment are treated with electroconvulsive therapy (ECT). The treatment is highly effective, and undoubtedly saves lives, but a range of factors, including side effect profile, the necessity for extended hospital care, and stigma, restricts its use.

A recent study has shown that patients who receive ketamine as the anaesthetic for ECT experience an earlier reduction in depressive symptoms and have a greater reduction in depressive symptoms than those receiving propofol (Okamoto et al., 2009). However, in this study eight ECT treatments were given to all participants so it is unknown whether ketamine could have reduced the number of treatments required. Overall, these studies suggest that as well as being a neuroprotective agent; ketamine may also have an antidepressant effect. Given these findings it is hypothesized that the use of ketamine in ECT treatment may reduce the number of ECT sessions required due to this drug's effects on depression ratings.

Our main research question is whether the use of ketamine as the anaesthetic for ECT treatment for depression improves the treatment outcome with respect to speed of response and reduction in side effects when compared to conventional anaesthesia.

• Study Type: Interventional
• Study Phase: Phase 4
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Triple (Participant, Investigator, Outcomes Assessor); Primary Purpose: Treatment
• Condition: Depression

Intervention

• Drug: Ketamine
  Ketamine used as the anaesthetic during ECT.
  Other Name: Ketalar
• Drug: Propofol
  The standard anaesthetic used for ECT.
  Other Name: Diprivan 1%

Study Arms

• Experimental: Ketamine
  Ketamine used as the anaesthetic during ECT.
  Intervention: Drug: Ketamine
• Active Comparator: Propofol
  Propofol, the standard anaesthetic, used during ECT.
  Intervention: Drug: Propofol

• Publications *: Fernie G, Currie J, Perrin JS, Stewart CA, Anderson V, Bennett DM, Hay S, Reid IC. Ketamine as the anaesthetic for electroconvulsive therapy: the KANECT randomised controlled trial. Br J Psychiatry. 2017 Jun;210(6):422-428. doi: 10.1192/bjp.bp.116.189134. Epub 2017 Mar 2. Erratum in: Br J Psychiatry. 2018 May;212(5):323.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: March 1, 2011): 40
• Original Estimated Enrollment: Same as current
• Actual Study Completion Date: February 2014
• Actual Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• between the ages of 18 and 65 years old
• diagnosed with depression and being referred for ECT
• American Society of Anesthesiologists (ASA) score of 1 or 2
• patient receiving ECT on an informal basis (i.e. consenting to treatment and able to give informed consent)

Exclusion Criteria:

• pre-existing neurological disease or cognitive impairment
• co-morbid psychiatric diagnoses
• pre-existing hypertension
• severe respiratory tract disease
• major cardiovascular disease
• pacemakers
• cerebrovascular disorder or malformation
• intracranial mass lesions
• seizure disorder
• intracranial electrode or clips
• intra-ocular pathology
• endocrine or metabolic disease
• severe hematologic disease
• severe fracture
• not able to give consent
• pregnancy

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years to 65 Years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United Kingdom

Administrative Information

• NCT Number: NCT01306760
• Other Study ID Numbers: CSO ETM/6
• Has Data Monitoring Committee: No
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Responsible Party: University of Aberdeen
• Study Sponsor: University of Aberdeen

Collaborators

• NHS Grampian
• Chief Scientist Office of the Scottish Government

Investigators

• Principal Investigator: Ian C Reid, PhD; University of Aberdeen

• PRS Account: University of Aberdeen
• Verification Date: September 2016